# Disclosure Statement

- This study was sponsored by Novartis Pharma AG, Basel, Switzerland
- Executive Committee and other investigators or their institutions received a consultancy fee
- Some authors are employees of Novartis and therefore eligible for stock and stock options

Clinicaltrials.gov: NCT00549757

# The Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

Hans-Henrik Parving[1,2], Barry M Brenner[3], John JV McMurray[4], Dick de Zeeuw[5], Steven M Haffner[6], Scott D Solomon[7], Nish Chaturvedi[8], Frederik Persson[9], A. S. Desai[7], Maria Nicolaides[10], Alexia Richard[10], Zhihua Xiang[10], Juergen Armbrecht[10] and Marc A Pfeffer[7] (on behalf of the ALTITUDE investigators)

[1]Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, Denmark; [2]Faculty of Health Science, Aarhus University, Denmark; [3] Renal Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, USA; [4]BHF Cardiovascular Research Centre, University of Glasgow, UK; [5] Department of Clinical Pharmacology, University Medical Centre Groningen, University of Groningen, The Netherlands; [6]Department of Medicine and Clinical Epidemiology, San Antonio, USA; [7] Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, USA; [8]Imperial College, London, UK; [9]Steno Diabetes Center, Gentofte, Denmark; [10]Novartis Pharma AG, Basel, Switzerland

# Kaplan-Meier estimate for time to the primary composite end-point



# ALTITUDE Hazard ratios for the individual components of the primary endpoint

| | Patients with events, n (%) | | | |
|---|---|---|---|---|
| | Aliskiren N = 4274 | Placebo N = 4287 | Hazard ratio (95 % CI) | P-value |
| Composite Endpoint | 767 (17.9) | 721 (16.8) | 1.08 (0.98, 1.20) | 0.142 |
| CV death | 239 (5.6) | 213 (5.0) | 1.13 (0.94, 1.36) | 0.184 |
| Resuscitated sudden death | 18 (0.4) | 8 (0.2) | 2.28 (0.99, 5.23) | 0.053 |
| Myocardial infarction | 142 (3.3) | 140 (3.3) | 1.02 (0.81, 1.29) | 0.858 |
| Stroke | 146 (3.4) | 118 (2.8) | 1.25 (0.98, 1.60) | 0.070 |
| Unplanned hospitalization for heart failure | 202 (4.7) | 219 (5.1) | 0.93 (0.77, 1.13) | 0.462 |
| Doubling of baseline serum creatinine | 205 (4.8) | 215 (5.0) | 0.96 (0.79, 1.16) | 0.650 |
| Onset of ESRD or renal death | 118 (2.8) | 108 (2.5) | 1.10 (0.85, 1.43) | 0.465 |
| Death | 375 (8.8) | 355 (8.3) | 1.07 (0.92, 1.23) | 0.388 |

Endpoints shown represent 92% of projected value of 1620 events for the primary composite endpoint
Adjusted for UACR and CVD history
Events adjudicated with cut-off date 31 Jan 2012

# ALTITUDE AEs/SAEs – Potassium Lab analysis